The Use of MitraClip for Symptomatic Patients with Hypertrophic Obstructive Cardiomyopathy

Felix Thomas1, Florian Rader, Robert J Siegel

  • 1Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Cardiology
|January 18, 2017
PubMed

Insights

The MitraClip device offers a safe and effective treatment for hypertrophic obstructive cardiomyopathy (HOCM), reducing left-ventricular outflow tract gradients and improving symptoms without causing conduction abnormalities.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Medical Devices

Background:

  • Symptomatic hypertrophic obstructive cardiomyopathy (HOCM) presents treatment challenges.
  • Current therapies like septal myectomy and alcohol septal ablation (ASA) carry risks of cardiac conduction abnormalities.
  • The MitraClip system presents a novel, lower-risk alternative.

Purpose of the Study:

  • To review published data on the use of the MitraClip system for symptomatic HOCM patients.
  • To evaluate the safety and efficacy of MitraClip in treating HOCM with systolic anterior motion (SAM).

Main Methods:

  • A review of 4 studies involving 15 symptomatic HOCM patients treated with MitraClip.
  • Consolidation of data on mitral regurgitation (MR), left-ventricular outflow tract (LVOT) gradient, and NYHA class.

Main Results:

  • MitraClip resolved SAM in all patients.
  • Significant reduction in MR and LVOT gradient (mean 75.8 to 11.0 mm Hg).
  • Symptomatic improvement and no associated conduction abnormalities or arrhythmias.

Conclusions:

  • MitraClip therapy is a potentially safe and effective option for symptomatic HOCM.
  • It may help high-risk patients avoid risks associated with traditional therapies.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
593
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
564
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
398
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
475
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
898
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.0K